Celine Jacquemont

Celine Jacquemont has extensive work experience in the field of translational sciences, diagnostics, biomarkers, and contract research. Celine is currently the Senior Director and Head of Translational Sciences at Bellicum Pharmaceuticals, Inc. Since joining the company in October 2022. Prior to that, they held the same position at Silverback Therapeutics from November 2021 to July 2022, and as a Director from December 2020 to November 2021. Celine also worked at Seattle Genetics as a Senior Manager of Diagnostics and Biomarkers from February 2019 to December 2020, and as a Manager from October 2016 to January 2019. Before that, they worked as a Senior Research Scientist at PhenoPath from June 2016 to October 2016, and as a Scientist in Contract Research from August 2014 to May 2016. Celine began their career as a Post-doctoral researcher/Research Associate at Fred Hutchinson Cancer Research Center from July 2005 to July 2014. Celine obtained their graduate degree at UMR 218, Institut Curie, where they worked as a Graduate Student from September 2000 to May 2005. Celine also worked as a Research Associate at Faculté des Sciences Biologiques et Pharmaceutiques, University René Descartes (Paris V), Paris from September 1999 to August 2000.

Celine Jacquemont's education history begins in 1996 when they started their Bachelor of Science (B.Sc.) degree in Cellular Biology and Physiology at the University Pierre et Marie CURIE (PARIS VI). Celine completed this degree in 1999.

From 1999 to 2000, they pursued their Master of Science (M.Sc.) in Drug Toxicology at the University René DESCARTES (PARIS V).

Following their master's degree, Celine Jacquemont enrolled in a Doctor of Philosophy (Ph.D.) program in Molecular and Cellular Biology - Cancer Biology at the University René DESCARTES (PARIS V), starting in 2000. Celine completed their Ph.D. in 2004.